Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066435 | 0.86 | HDAC1 (0.42) | HDAC1HDAC8HDAC6SCN10AMAPK1 | |
| SCHEMBL19066414 | 0.80 | KDM4E (0.43) | HDAC1HDAC8HDAC6PDE4BPDE4D | |
| SCHEMBL17040265 | 0.75 | MAPT (0.41) | HDAC1HDAC8HDAC6SCN10APOLB | |
| SCHEMBL29204552 | 0.75 | PTPN11 (0.47) | POLBGAAPDE4D | |
| SCHEMBL24297133 | 0.75 | PTPN11 (0.35) | POLBGAAMAPK1PDE4DMAPT | |
| SCHEMBL30484467 | 0.74 | KMO (0.41) | HDAC1HDAC8HDAC6SCN10A | |
| SCHEMBL17037213 | 0.74 | HDAC1 (0.39) | HDAC1HDAC8HDAC6SCN10AMAPK1 | |
| SCHEMBL19066438 | 0.74 | KMO (0.41) | HDAC1HDAC8HDAC6SCN10A | |
| SCHEMBL2221957 | 0.74 | HDAC1 (0.67) | HDAC1HDAC8HDAC6SCN10AGAA | |
| SCHEMBL2824061 | 0.73 | HDAC1 (0.50) | HDAC1HDAC8HDAC6SCN10AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366573-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| US-20220117944-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20220117944-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20200171006-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200171006-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
| US-10588893-B2 | Ointment containing an oxazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-17 | — | — | US | disclosed |
| US-10588893-B2 | Ointment containing an oxazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-17 | — | — | US | disclosed |
| US-20190000810-A1 | OINTMENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| US-20190000810-A1 | OINTMENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| EP-3397619-A1 | OINTMENT | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017115780-A1 | OINTMENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017115780-A1 | OINTMENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366573-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | PDE12, PDE4B, PDE4A | HDAC1 142/4885HDAC8 260/4885HDAC6 483/4885 |
| US-20200171006-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | PDE12, PDE4B, PDE4A | HDAC1 142/4885HDAC8 260/4885HDAC6 483/4885 |
| US-20220117944-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | PDE12, PDE4B, PDE4A | HDAC1 142/4885HDAC8 260/4885HDAC6 483/4885 |
| US-10588893-B2 | Ointment containing an oxazole compound | PDE12, PDE4B, PDE4A | HDAC1 142/4885HDAC8 260/4885HDAC6 483/4885 |
| US-20190000810-A1 | OINTMENT | PDE12, PDE4B, PDE4A | HDAC1 199/4885HDAC8 355/4885HDAC6 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.